Form 4: Arteris Inc. VP and General Counsel Paul Alpern Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Paul Alpern, VP and General Counsel of Arteris, Inc., exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan on August 1, 2024.
Summary
- On August 1, 2024, Paul Alpern, VP and General Counsel of Arteris, Inc., executed stock options to acquire 11,250 shares of common stock.
- These options were exercised at prices of $0.56 and $0.60 per share.
- Simultaneously, Alpern sold 11,250 shares of common stock at a weighted average price ranging from $7.45 to $8.23.
- The transactions were conducted under a 10b5-1 trading plan adopted on August 16, 2023.
- Following these transactions, Alpern directly owns 74,563 shares of Arteris, Inc. common stock and 100,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions under a pre-arranged plan. There's no indication of unusual activity or concern.
Positives
- The transactions were executed under a pre-existing 10b5-1 trading plan, indicating a planned and transparent approach to stock transactions.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. The use of a 10b5-1 trading plan is a standard practice to allow insiders to sell shares without concerns about potential insider trading violations.
Comparison to Industry Standards
- The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the semiconductor and technology sectors, such as ARM Holdings, Cadence Design Systems, and Synopsys.
- These plans allow insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information.
- The reported weighted average sale price of Arteris shares is within the typical range observed for similar technology companies, reflecting market conditions and investor sentiment.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan suggests the transactions were planned and not based on inside information.
Key Dates
| Date | Description |
|---|---|
| August 26, 2020 | 25% of the total shares vested; thereafter, 1/48th of the total shares have vested monthly for 3 years, beginning on September 26, 2020. |
| July 23, 2021 | 25% of the total shares vested; thereafter, 1/48th of the total shares vest monthly for 3 years, beginning on August 23, 2021. |
| August 16, 2023 | Date the Reporting Person adopted the 10b5-1 trading plan. |
| August 1, 2024 | Date of the reported transactions: exercising stock options and selling shares. |
| August 5, 2024 | Date of signature on the Form 4. |
| October 23, 2029 | Expiration date of common stock options. |
| July 22, 2030 | Expiration date of common stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.